Neurology

Your Article Summary

See Latest Articles

Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas
Cancer, 06/01/09

Cassier PA et al. – Gemcitabine-oxaliplatin combination (GEMOX) is active and well tolerated in pretreated pts with metastatic neuroendocrine tumors.

• Study of GEMOX efficacy in treatment of pts with metastatic neuroendocrine tumors
• GEMOX treatment for 20 consecutive pts with progressive disease, most cases after failure of other chemotherapy regimens (median 2 regimens)
• Follow-up for evidence of toxicity, response, and survival
• Exclusion from efficacy analysis of 2 pts chemotherapy-naive at treatment initiation

• Toxicity manageable overall
• Treatment discontinuation due to oxaliplatin-induced neurotoxicity (grade 2) in 6 pts (30%)
• Partial response for 3 (17%) of 18 pts
• Median progression-free survival: 7 mo
• Median overall survival: 23.4 mo

Today in Neuroendocrinology...keeping you current

Receive free subspecialty "5-minute updates" via email

Medical treatment of Cushing's disease: Overview and recent findings
International Journal of General Medicine, 10/21/09

Predicting Recurrence of Nonfunctioning Pituitary Adenomas
Journal of Clinical Endocrinology and Metabolism, 10/15/09

The pituitary-adrenal axis in adult thalassaemic patients
European Journal of Endocrinology, 11/02/09

See All of Neuroendocrinology

Today in Neurologic Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Primary central nervous system lymphoma: an update
Current Opinion in Oncology, 10/12/09

Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial
The Lancet Oncology - Online First, 10/07/09

Medulloblastoma in childhood: revisiting intrathecal therapy in infants and children
Cancer Chemotherapy and Pharmacology, 10/29/09

See All of Neurologic Oncology